The Longevity-Associated Variant of BPIFB4 Reduces Senescence in Glioma Cells and in Patients’ Lymphocytes Favoring Chemotherapy Efficacy

The Longevity-Associated Variant of BPIFB4 Reduces Senescence in Glioma Cells and in Patients’ Lymphocytes Favoring Chemotherapy Efficacy

Glioblastoma (GBM) is the most common primary brain cancer with the median age at diagnosis around 64 years, thus pointing to aging as an important risk factor. Indeed, aging, by increasing the senescence burden, is configured as a negative prognostic factor for GBM stage. Furthermore, several anti-...

Full description

Bibliographic Details
Main Authors: Annibale Alessandro Puca, Valentina Lopardo, Francesco Montella, Paola Di Pietro, Daniela Cesselli, Irene Giulia Rolle, Michela Bulfoni, Veronica Di Sarno, Giorgio Iaconetta, Pietro Campiglia, Carmine Vecchione, Antonio Paolo Beltrami, Elena Ciaglia
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cells
Subjects:
senescence
glioma
longevity
PBMCs
chemotherapy
Online Access:https://www.mdpi.com/2073-4409/11/2/294

Internet

https://www.mdpi.com/2073-4409/11/2/294

Similar Items